

Company name: Minapharm pharmaceutical

an audited financial indicator for the financial year period ended on 31/03/2024.

Currency: EGP

(The form should include the company's comment on the results of the business with the most important factors that led to profit/loss)

First, the financial indicators

(A) statement of profit or loss for the year/period ended on 31/03/2024.

	Current period	comparative financial statements	change%
Revenue/sales	674,617,846	618,107,548	9%
Total profit (loss)	165,880,851	188,385,926	-12%
The ratio of total profit to revenue/sales	0.32	0.41	-22%
Net profit (loss) before tax from continuing activities	1,343,262	45,995,651	-97%
Net profit (loss) before tax from non-continuing activities (if any)	-	-	0%
Net profit (loss) after tax	676,053	34,032,101	-98%
Earnings / (losses) per share (EPS)	0	2.56	-100%
Diluted share of profit / loss (if any)	-	-	0%

شركة مينا فارم للأدوية والصناعات الكيماوية
ط ٢ ش. البرديس من أسماء فهمى
خلف الرقابة الإدارية - أرض الجولف
م. اسم

Head Office: 2T Taksim Asmaa Fahmy Nasr City – Cairo – Egypt
Factory: 10th of Ramadan City - Egypt

(B) Statement of financial position in 31/03/2024.

	Current period	comparative financial year (previous Year)	change%
Net working capital	761,170,021-	602,862,917-	26%
Owner's equity	1,180,137,758	1,179,461,705	0.06%
Paid capital	122,934,400	122,934,400	0%
Reserves	291,996,136	291,996,136	0%
Retained earnings	834,157,704	627,652,811	33%
The profit (loss) of the period	676,053	206,504,893	-99.67%
Other			
Treasury Shares	69,626,535	69,626,535	0%

(C) cash flow statement for the year 31/03/2024

	Current period	comparative financial statements	Change%
Cash flows from (to) operating activities	88,612,179-	231,703,557	-138%
Cash flows from (to) investment activities	132,260,219-	498,758,905-	-73%
Cash flows from (to) financing activities	540,290,070	491,812,696	10%

Second: Material events that have occurred since the date of the financial results till now and should be disclosed.

None

شركة مينا فارم للأدوية والصناعات الكيماوية
ط ٢ ش. البرديس من أسماء فهمي
خلف الرقابة الإدارية - أرض الجولف
دارس

Agree

We acknowledge that the above-mentioned statements are extracted from the Company's financial statements issued by the Board of Directors held on 22 /05 / 2024 and have not yet issued the auditor's report and we undertake to promptly disclose to FRA and EGX if any change in these statements as soon as it occurs until the submission of the signed financial statements which we undertake to send immediately after Issue the auditor/auditor's report before the beginning of the trading session of the following day according to the date recorded in the auditor's report, which we expect to be a " clean" report .

(if amended, please state the reasons given in the annex (No. 2)).

Investor relations officer

Chairman

Date 22 / 05 / 2024

The company's stamp.

شركة مينافارم للأدوية والصناعات الكيماوية
ط ٢ ش. البرديس من أسماء فهمي
خلف الرقابة الإدارية - أرض الجولف
د/ اسم